Andera Partners reinvests in Exciva GmbH's €51 million Series B round to support the development of Deraphan, a treatment for agitation in Alzheimer's disease.
Information on the Target
Andera Partners has confirmed its reinvestment in Exciva GmbH as part of a €51 million ($59 million) Series B financing round, which is primarily aimed at advancing its lead program into a Phase 2 clinical study. Exciva is a biopharmaceutical company specializing in developing innovative therapeutic compounds for neuropsychiatric conditions, particularly focusing on Alzheimer’s disease (AD). The financing round is led by Gimv and EQT Life Sciences, with notable contributions from both new and existing investors, including Fountain Healthcare Partners and LifeArc Ventures.
The funding will predominantly support Phase 2 studies for Deraphan, a promising treatment aimed at alleviating agitation in Alzheimer’s patients. Deraphan consists of a combination of two clinically validated products and one novel chemical entity, designed to enhance treatment efficacy and optimize the risk/benefit ratio compared to existing therapies. Previous Phase 1 trials have affirmed the safety and tolerability of Deraphan.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The biotechnology sector in Europe has been experiencing significant growth, driven by advancements in therapeutic areas and regulatory support. Governments across the
Similar Deals
Andera Partners
invested in
Exciva GmbH
in 2021
in a Series B deal
Disclosed details
Transaction Size: $59M